OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA). Read More
Recent Posts
Romanian Inflation Ends Tumultuous Year in Politics Close to 10%
UK Boosts Support For Offshore Wind in Bumper Auction
Ireland Is Trying to Get Back on the Data Center Bandwagon
Notice Concerning Change of Representative Executive Officer
Polish Recycler Bets Millions on Europe’s Critical Metals Push
Blistering Metals Rally Sends Silver, Tin and Copper to Records
Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities
TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
